Astec LifeSciences Limited Stocks

543Last Updated 02.04.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

₹ 130.55M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
543
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Astec LifeSciences Limited, together with its subsidiaries, manufactures, distributes, and sells agrochemicals active ingredients and pharmaceutical intermediates in India. It manufactures a range of fungicides, insecticides, herbicides, and intermediates, such as triazole fungicides, heterocyclic herbicides, sulfonyl urea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, and silane derivatives; fluorinated aromatic amines, pyridine derivatives, aromatic carboxylic acids, benzyl alcohols, ketones and benzophenones, and heterocyclic mercaptans; fluorinated aromatic, aliphatic, and heterocyclic intermediates; heterocyclic mercaptans, thiopyrimidines, aromatic mercaptans, heterocyclic sulfonyl chlorides, heterocyclic sulphonamides, heterocyclic carbamates, thiourium salts, alkyl and aryl chloroformates, substituted pyrimidine diones, and pyrazolones; and substituted 1,2- and 1,3- pyrimidines. The company's products also comprise pyrazolyl aromatic ketones, morpholine derivatives, aromatic azo compounds, substituted triazines, imidate ethers, mesylated intermediates, substituted epoxides, ketals and bromo ketals, aromatic and aliphatic ethers, cyclopropyl ethers, cyclopropyl aldehydes and ketones, conjugated ketones, acetophenone derivatives, pinacolone derivatives, aliphatic and aromatic carboxylic acids, aliphatic and aromatic acid chlorides, halogenated and non-halogenated anhydrides, aliphatic alkenes, and halo alkanes; and aliphatic and aromatic brominated derivatives, cyanides, esters, carboxamides, amines, and alcohols and diols. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited is a subsidiary of Godrej Agrovet Limited.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Very favourable
7/7

The average target price of ASTEC.NS is 876 and suggests 61% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks